Abstract 59P
Background
Although anti-epidermal growth factor receptor (EGFR) therapy has established efficacy in RAS/BRAF wild type (WT) mCRC, 10-20% of WT patients exhibit primary resistance to this treatment. Biomarker discovery has mainly focused on tumor-specific DNA mutations, which suffer from variable mutation frequencies among patients. Epigenetic abnormalities, such as promoter hypermethylation, represent a common and early event in carcinogenesis, making it promising for resistance detection. In fact, several studies have shown an association between DNA methylation patterns and resistance to anti-EGFR therapy in CRC. To validate and build upon these findings, we investigated the methylomes of primary tumors with resistant and responsive phenotypes.
Methods
We isolated DNA from 15 primary CRC tumors. These DNA samples were subjected to Enzymatic Methyl-Sequencing (EMSeq), creating a genome-wide methylation dataset. We calculated methylation levels at CpGs and evaluated their correlation with resistance status. Based on the methylation values, a differential methylation analysis was performed using a modified linear mixed regression model. The CpGs were ranked based on the largest Δmethylation values and most significant p-values across the three patient groups. We performed a false discovery rate (FDR) evaluation, which led to the selection of differentially methylated CpGs (DMCs) with the highest likelihood of being genuine associations. Additionally, the DMCs were used as input for gene set enrichment analysis (GSEA).
Results
The GSEA revealed significant enrichment in 1 KEGG and 8 Reactome pathways, including MAPK-related, Akt and Wnt signaling. A gene ontology (GO) overrepresentation analysis was conducted on the significant genes. Notably, the most prominent GO categories were GTPase activity for molecular function and response to oxidative stress for biological processes.
Conclusions
We have created a comprehensive dataset of methylation sites with a substantial effect on conferring resistance to anti-EGFR therapy in CRC patients. In addition to identifying critical DMCs, the pathways hold potential as a rich source of predictive biomarkers.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
University of Antwerp.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
84P - Profiling of lipid-loaded macrophages in melanoma
Presenter: Marta Pandini
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Whole-genome CRISPR screening identifies chemosensor receptors as key regulators of the cancer-macrophage crosstalk
Presenter: Giulia Marelli
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Regulation of cancer progression through the gut microbiome and immuno-nutrition
Presenter: Anikka Swaby
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Macrophage ontogeny underlies functional programs and drives brain tumor progression
Presenter: Miranda Yu
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluating the infiltration of anti-NKG2DL CAR-T cells into a 3D cell culture developed in a Vitvo cartridge bioreactor
Presenter: Aigul Valiullina
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Neutrophils as producers of endothelial growth factor in the progression of kidney cancer
Presenter: Ilseya Myagdieva
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: A systematic review
Presenter: Omar Mubarak
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Reduction in the relative lymphocyte count as a predictive biomarker for serious immune-related adverse events in patients with metastatic non-small cell lung cancer on immunotherapy: Single institution experience
Presenter: Antoan Garev
Session: Cocktail & Poster Display session
Resources:
Abstract
93P - A new platform for fast-track molecular stratification of endometrial carcinomas enabling timely treatment decisions in precision oncology
Presenter: Susanne Walz
Session: Cocktail & Poster Display session
Resources:
Abstract